Eric Paul Wehrenberg-Klee, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Yttrium Radioisotopes | 6 | 2021 | 107 | 2.410 |
Why?
|
Cryosurgery | 5 | 2024 | 475 | 1.800 |
Why?
|
Carcinoma, Hepatocellular | 8 | 2021 | 2299 | 1.460 |
Why?
|
Liver Neoplasms | 11 | 2023 | 4319 | 1.170 |
Why?
|
Immunotherapy | 10 | 2024 | 4642 | 1.070 |
Why?
|
Embolization, Therapeutic | 7 | 2023 | 1412 | 0.790 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2021 | 127 | 0.720 |
Why?
|
Cancer Vaccines | 1 | 2022 | 1046 | 0.480 |
Why?
|
Radiography, Interventional | 2 | 2019 | 1112 | 0.480 |
Why?
|
Positron-Emission Tomography | 8 | 2021 | 6465 | 0.450 |
Why?
|
Granzymes | 3 | 2020 | 276 | 0.430 |
Why?
|
Microspheres | 4 | 2023 | 787 | 0.410 |
Why?
|
Combined Modality Therapy | 6 | 2024 | 8552 | 0.390 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1229 | 0.370 |
Why?
|
Neoplasms | 6 | 2024 | 22075 | 0.340 |
Why?
|
Molecular Imaging | 1 | 2016 | 818 | 0.320 |
Why?
|
Receptor, erbB-3 | 2 | 2021 | 143 | 0.320 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1613 | 0.310 |
Why?
|
Patient Selection | 2 | 2019 | 4279 | 0.290 |
Why?
|
Catheter Ablation | 3 | 2021 | 2758 | 0.270 |
Why?
|
Disease Models, Animal | 2 | 2024 | 18137 | 0.260 |
Why?
|
Glycolates | 1 | 2023 | 40 | 0.230 |
Why?
|
Splenic Artery | 1 | 2024 | 57 | 0.230 |
Why?
|
Injections, Intralesional | 1 | 2024 | 278 | 0.220 |
Why?
|
Stochastic Processes | 1 | 2023 | 354 | 0.210 |
Why?
|
Radiometry | 2 | 2023 | 813 | 0.190 |
Why?
|
Aneurysm | 1 | 2024 | 337 | 0.180 |
Why?
|
Portal Pressure | 1 | 2020 | 60 | 0.180 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 1039 | 0.180 |
Why?
|
Radiopharmaceuticals | 2 | 2020 | 2634 | 0.170 |
Why?
|
Radiation Pneumonitis | 1 | 2020 | 102 | 0.170 |
Why?
|
Technology | 1 | 2022 | 291 | 0.170 |
Why?
|
Tissue Distribution | 2 | 2021 | 2262 | 0.170 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2470 | 0.160 |
Why?
|
Genes, cdc | 1 | 2018 | 115 | 0.160 |
Why?
|
Liver Transplantation | 2 | 2021 | 2325 | 0.150 |
Why?
|
Hypertension, Portal | 1 | 2020 | 226 | 0.150 |
Why?
|
Kidney Neoplasms | 2 | 2013 | 4312 | 0.150 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13627 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2021 | 248 | 0.150 |
Why?
|
Cell Line, Tumor | 6 | 2021 | 16932 | 0.150 |
Why?
|
Liver Function Tests | 1 | 2019 | 524 | 0.140 |
Why?
|
Safety | 1 | 2021 | 1148 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 3218 | 0.130 |
Why?
|
Immunologic Factors | 2 | 2022 | 1588 | 0.130 |
Why?
|
Angiography | 1 | 2020 | 1605 | 0.120 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1660 | 0.120 |
Why?
|
Hepatectomy | 1 | 2018 | 559 | 0.120 |
Why?
|
Quinazolines | 1 | 2021 | 1363 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1268 | 0.120 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3844 | 0.110 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21029 | 0.110 |
Why?
|
Brachytherapy | 1 | 2021 | 1238 | 0.110 |
Why?
|
Treatment Outcome | 10 | 2021 | 64981 | 0.110 |
Why?
|
Mice | 9 | 2024 | 81209 | 0.110 |
Why?
|
Octreotide | 1 | 2013 | 153 | 0.100 |
Why?
|
Receptors, Somatostatin | 1 | 2013 | 136 | 0.100 |
Why?
|
Humans | 27 | 2024 | 760613 | 0.100 |
Why?
|
Radiotherapy Dosage | 1 | 2019 | 2897 | 0.100 |
Why?
|
Lung | 2 | 2020 | 9994 | 0.090 |
Why?
|
Intestinal Neoplasms | 1 | 2013 | 311 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2554 | 0.090 |
Why?
|
Colonic Neoplasms | 2 | 2018 | 2526 | 0.080 |
Why?
|
Lymphoma | 1 | 2018 | 1899 | 0.080 |
Why?
|
Animals | 9 | 2024 | 167960 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20509 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13505 | 0.070 |
Why?
|
Neuroendocrine Tumors | 1 | 2013 | 650 | 0.070 |
Why?
|
Female | 13 | 2024 | 391246 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2018 | 3486 | 0.070 |
Why?
|
Male | 12 | 2024 | 359718 | 0.070 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22020 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5251 | 0.070 |
Why?
|
Peptides | 1 | 2018 | 4354 | 0.070 |
Why?
|
Gallium Radioisotopes | 2 | 2018 | 195 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1529 | 0.060 |
Why?
|
Surgery, Computer-Assisted | 1 | 2013 | 1007 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2013 | 1178 | 0.060 |
Why?
|
Retrospective Studies | 9 | 2024 | 80345 | 0.060 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 2180 | 0.050 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58980 | 0.050 |
Why?
|
Pain, Postoperative | 1 | 2013 | 1720 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10442 | 0.050 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 1 | 2020 | 66 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6853 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2024 | 15286 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14661 | 0.050 |
Why?
|
Liver Circulation | 1 | 2020 | 159 | 0.050 |
Why?
|
Microwaves | 1 | 2021 | 185 | 0.040 |
Why?
|
Middle Aged | 9 | 2024 | 220359 | 0.040 |
Why?
|
Aged | 8 | 2024 | 169143 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9185 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 600 | 0.040 |
Why?
|
Somatostatin | 1 | 2020 | 447 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5697 | 0.040 |
Why?
|
Prognosis | 2 | 2016 | 29661 | 0.040 |
Why?
|
Retroperitoneal Space | 1 | 2018 | 173 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2020 | 743 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20080 | 0.040 |
Why?
|
Biotin | 1 | 2018 | 253 | 0.040 |
Why?
|
Prospective Studies | 1 | 2021 | 54306 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2017 | 162 | 0.030 |
Why?
|
Risk Assessment | 3 | 2024 | 24102 | 0.030 |
Why?
|
Adult | 6 | 2024 | 220007 | 0.030 |
Why?
|
Time Factors | 3 | 2024 | 40139 | 0.030 |
Why?
|
Pelvis | 1 | 2018 | 743 | 0.030 |
Why?
|
Chemical Fractionation | 1 | 2013 | 62 | 0.030 |
Why?
|
Droperidol | 1 | 2013 | 21 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2020 | 1957 | 0.030 |
Why?
|
Solubility | 1 | 2013 | 1088 | 0.020 |
Why?
|
Midazolam | 1 | 2013 | 267 | 0.020 |
Why?
|
Risk Factors | 3 | 2024 | 74333 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2943 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5305 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6544 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1931 | 0.020 |
Why?
|
Hemodynamics | 1 | 2020 | 4173 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2017 | 1765 | 0.020 |
Why?
|
Thrombosis | 1 | 2024 | 3051 | 0.020 |
Why?
|
Fentanyl | 1 | 2013 | 434 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 1975 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5201 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41337 | 0.020 |
Why?
|
Models, Biological | 1 | 2023 | 9468 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6216 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3607 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1895 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2829 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 6130 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9335 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3583 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6771 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 58748 | 0.020 |
Why?
|
Pain Measurement | 1 | 2013 | 3527 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 10826 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39262 | 0.010 |
Why?
|
Rats | 1 | 2013 | 23709 | 0.010 |
Why?
|
Child | 1 | 2018 | 79799 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 87809 | 0.010 |
Why?
|